Obesity
A multifaceted risk factor:
Addressing obesity's impact across the disease spectrum
2.8 million people die every year as a result of obesity. At the same time, investment in research and development for obesity therapies is ushering in a new era of effective medications for this disease. Explore the implications of obesity as a risk factor across the disease spectrum, and how this may impact treatment, drug development and clinical trials for obesity.
ICON survey report:
Trends and challenges in obesity research and clinical trials
This survey investigates the opinions, experiences and predictions of a variety of individuals best positioned to provide an overview of current obesity drug and device development — and where it is likely to go in the future.
Obesity blogs and media contributions
-
Media article: Advancing Research and Development of Multi-indication and Combination Therapies for Obesity
In this article, ICON's Jack Martin explores the impact of comorbidities on obesity therapeutic development including strategic and innovative approaches to therapeutic d
-
Media article: Overcoming challenges in obesity-related clinical trials
Recent advancements in obesity treatments have spotlighted the field for healthcare providers and developers. In this article from Drug Discovery World, ICON experts shar
-
Blog: Diabesity: Overlapping pathophysiology informs multi-indication treatment
As recognition of the overlap between obesity and diabetes has grown, so have efforts to develop treatments that can treat the two conditions in tandem.
-
Media article: Insight into obesity-related clinical research
In an interview with Contract Pharma, ICON’s Adrienne Stoudenmire and Alan Baldridge discuss current obesity R&D trends, challenges associated with obesity-related clinical research, and opportunities in this sector.
-
Media article: The State of Obesity-Related Clinical Research: A Q&A session with ICON's Simon Bruce
ICON’s Simon Bruce, Vice President of Internal Medicine and Drug Development Solutions sits down for a Q&A with Pharmaceutical Executive and gives an overview on the obesity survey carried out by ICON in January 2024.
-
Media article: Diabesity: Implications for treatment and drug development
In this Journal for Clinical Studies’ article, Simon Bruce and Jack Martin discuss the overlap in pathophysiology and treatment of diabetes and obesity along with considerations for streamlining the clinical development of treatments that have therapeutic promise for both conditions.
-
Media article: ICON announces results from survey on obesity-related clinical research
This news article, from Applied Clinical Trials, outlines findings from ICON’s recent survey of over 100 industry professionals on their opinions on future research within the therapeutic area of obesity treatment.
-
Media article: ICON survey stresses combo therapies in obesity care
This news piece from The Clinical Trial Vanguard provides an overview of the findings from ICON’s recent survey of professionals engaged in obesity-related clinical research. It outlines that most respondents believe that obesity therapy trials should measure multiple outcomes due to the overlap between obesity and related comorbidities.
Interdisciplinary expertise in obesity research services
ICON’s highly experienced clinical and therapeutic teams have expertise in conducting trials across a wide range of therapeutic areas including obesity, diabetes, cardiometabolic disorders and hepatology including MASH.